Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Moderna, Inc.MRNA · Entity 2025 | General Counsel and Secretary | May 27, 2021 | May 28, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Moderna, Inc.
Report date May 27, 2021 · Filed May 28, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 901 |
Ending reported balance
After 2021-05-27 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-05-27 · Exercise / conversion · Acquired 6,600 · Balance 7,501 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Row 2 · 2021-05-27 · Sale · Disposed 6,600 · Balance 901 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.85 · Expires 2028-06-26 | Direct | 328,352 |
Reported balance
After 2021-05-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-05-27 · Exercise / conversion · Disposed 6,600 · Balance 328,352 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. F2: 25% of this option will vest and become exercisable on April 9, 2019 with the remainder vesting in 12 equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020.
F2: 25% of this option will vest and become exercisable on April 9, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALBANY MOLECULAR RESEARCH INC
Report date August 31, 2017 · Filed September 05, 2017
Section 16 reporting ended · disclosed 2017-09-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,138 |
Reported balance
After 2017-08-28 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2017-08-28 · Gift · Disposed 9,857 · Balance 52,138 F1: This transaction involved a gift of securities by Ms. Lori Henderson. Ms. Henderson disclaims beneficial ownership of these shares and this report shall not be deemed an admission that Ms. Henderson is the beneficial owner of such securities for the purpose of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 66,717 |
Reported balance
After 2017-08-31 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2017-08-31 · Grant · Acquired 4,722 · Balance 66,717 |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2017-08-31 · Disposition to issuer · Disposed 66,717 · Balance 0 F2: Disposed of pursuant to the Agreement and Plan of Merger, dated as of June 5, 2017, by and among Albany Molecular Research, Inc. ("AMRI"), UIC Parent Corporation ("UIC Parent"), and UIC Merger Sub, Inc. ("UIC Sub") (the "Merger Agreement"). The Merger Agreement provides that each share of AMRI common stock and each outstanding restricted stock unit automatically be canceled and converted into the right to receive $21.75 in cash, without interest and less any applicable withholding taxes (the "Merger Consideration"). |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $4.87 · Expires 2021-02-04 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-08-31 · Disposition to issuer · Disposed 50,000 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $5.25 · Expires 2021-06-02 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-08-31 · Disposition to issuer · Disposed 17,500 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.93 · Expires 2022-02-17 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-08-31 · Disposition to issuer · Disposed 4,375 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.93 · Expires 2022-02-17 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-08-31 · Disposition to issuer · Disposed 4,375 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.93 · Expires 2022-02-17 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-08-31 · Disposition to issuer · Disposed 17,500 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $5.99 · Expires 2023-01-31 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2017-08-31 · Disposition to issuer · Disposed 4,375 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $5.99 · Expires 2023-01-31 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2017-08-31 · Disposition to issuer · Disposed 17,500 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $5.99 · Expires 2023-01-31 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2017-08-31 · Disposition to issuer · Disposed 4,375 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $5.99 · Expires 2023-01-31 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2017-08-31 · Disposition to issuer · Disposed 4,375 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $10.43 · Expires 2024-02-04 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2017-08-31 · Disposition to issuer · Disposed 29,167 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $17.05 · Expires 2025-03-02 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2017-08-31 · Disposition to issuer · Disposed 22,893 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $15.77 · Expires 2026-02-04 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2017-08-31 · Disposition to issuer · Disposed 29,066 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.41 · Expires 2027-02-08 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2017-08-31 · Disposition to issuer · Disposed 44,251 · Balance 0 F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction involved a gift of securities by Ms. Lori Henderson. Ms. Henderson disclaims beneficial ownership of these shares and this report shall not be deemed an admission that Ms. Henderson is the beneficial owner of such securities for the purpose of Section 16 or any other purpose.
F2: Disposed of pursuant to the Agreement and Plan of Merger, dated as of June 5, 2017, by and among Albany Molecular Research, Inc. ("AMRI"), UIC Parent Corporation ("UIC Parent"), and UIC Merger Sub, Inc. ("UIC Sub") (the "Merger Agreement"). The Merger Agreement provides that each share of AMRI common stock and each outstanding restricted stock unit automatically be canceled and converted into the right to receive $21.75 in cash, without interest and less any applicable withholding taxes (the "Merger Consideration").
F3: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2021 Filed Apr 2, 2021 14:30 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,600 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-21-012672 · form4.xml · derivative · entry 3 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,476 Underlying: Common Stock · 6,600 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 14:30 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 6,600 | $132.51 | $874,566.00 |
DisclosureSEC source: 0001127602-21-012672 · form4.xml · nonDerivative · entry 2 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 14:30 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 6,600 | $20.93 | $138,138.00 |
DisclosureSEC source: 0001127602-21-012672 · form4.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 20:22 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,600 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-21-012597 · form4.xml · derivative · entry 3 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,076 Underlying: Common Stock · 6,600 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 20:22 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 6,600 | $123.30 | $813,780.00 |
DisclosureSEC source: 0001127602-21-012597 · form4.xml · nonDerivative · entry 2 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 20:22 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 6,600 | $20.93 | $138,138.00 |
DisclosureSEC source: 0001127602-21-012597 · form4.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 20:33 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,600 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-21-012107 · form4.xml · derivative · entry 3 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,676 Underlying: Common Stock · 6,600 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 20:33 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 6,600 | $126.88 | $837,408.00 |
DisclosureSEC source: 0001127602-21-012107 · form4.xml · nonDerivative · entry 2 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 20:33 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 6,600 | $20.93 | $138,138.00 |
DisclosureSEC source: 0001127602-21-012107 · form4.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 20:11 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,600 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-21-012023 · form4.xml · derivative · entry 3 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,276 Underlying: Common Stock · 6,600 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 20:11 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 6,600 | $145.55 | $960,630.00 |
DisclosureSEC source: 0001127602-21-012023 · form4.xml · nonDerivative · entry 2 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 20:11 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 6,600 | $20.93 | $138,138.00 |
DisclosureSEC source: 0001127602-21-012023 · form4.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 21:18 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 216 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-21-011589 · form4.xml · derivative · entry 5 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,876 Underlying: Common Stock · 216 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. F3 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 21:18 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,384 | $0.00 Strike: $25.93 | $0.00 |
DisclosureSEC source: 0001127602-21-011589 · form4.xml · derivative · entry 4 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,155 Underlying: Common Stock · 6,384 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 21:18 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 6,600 | $144.39 | $952,974.00 |
DisclosureSEC source: 0001127602-21-011589 · form4.xml · nonDerivative · entry 3 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 21:18 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 216 | $20.93 | $4,520.88 |
DisclosureSEC source: 0001127602-21-011589 · form4.xml · nonDerivative · entry 2 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 21:18 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 6,384 | $25.93 | $165,537.12 |
DisclosureSEC source: 0001127602-21-011589 · form4.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 20:11 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,600 | $0.00 Strike: $25.93 | $0.00 |
DisclosureSEC source: 0001127602-21-011404 · form4.xml · derivative · entry 3 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,539 Underlying: Common Stock · 6,600 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. F2 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 20:11 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 6,600 | $148.50 | $980,100.00 |
DisclosureSEC source: 0001127602-21-011404 · form4.xml · nonDerivative · entry 2 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 20:11 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 6,600 | $25.93 | $171,138.00 |
DisclosureSEC source: 0001127602-21-011404 · form4.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 22:53 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,600 | $0.00 Strike: $25.93 | $0.00 |
DisclosureSEC source: 0001127602-21-010462 · form4.xml · derivative · entry 3 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,139 Underlying: Common Stock · 6,600 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. F2 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 22:53 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 6,600 | $133.29 | $879,714.00 |
DisclosureSEC source: 0001127602-21-010462 · form4.xml · nonDerivative · entry 2 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 22:53 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 6,600 | $25.93 | $171,138.00 |
DisclosureSEC source: 0001127602-21-010462 · form4.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 21:03 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,600 | $0.00 Strike: $25.93 | $0.00 |
DisclosureSEC source: 0001127602-21-010069 · form4.xml · derivative · entry 3 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,739 Underlying: Common Stock · 6,600 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. F2 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 21:03 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 6,600 | $127.11 | $838,926.00 |
DisclosureSEC source: 0001127602-21-010069 · form4.xml · nonDerivative · entry 2 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 21:03 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 6,600 | $25.93 | $171,138.00 |
DisclosureSEC source: 0001127602-21-010069 · form4.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 21:28 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,600 | $0.00 Strike: $25.93 | $0.00 |
DisclosureSEC source: 0001127602-21-009526 · form4.xml · derivative · entry 3 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,339 Underlying: Common Stock · 6,600 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 21:28 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 6,600 | $128.58 | $848,628.00 |
DisclosureSEC source: 0001127602-21-009526 · form4.xml · nonDerivative · entry 2 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 21:28 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 6,600 | $25.93 | $171,138.00 |
DisclosureSEC source: 0001127602-21-009526 · form4.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:13 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,600 | $0.00 Strike: $25.93 | $0.00 |
DisclosureSEC source: 0001127602-21-009397 · form4.xml · derivative · entry 3 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,939 Underlying: Common Stock · 6,600 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. F3 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:13 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 6,600 | $153.77 | $1,014,882.00 |
DisclosureSEC source: 0001127602-21-009397 · form4.xml · nonDerivative · entry 2 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:13 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 6,600 | $25.93 | $171,138.00 |
DisclosureSEC source: 0001127602-21-009397 · form4.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020. F2 · balance_after: Includes 220 shares acquired under the Moderna, Inc. 2018 Employee Stock Purchase Plan on November 30, 2020. Read SEC document |
| October 21, 2020 Filed Oct 23, 2020 20:32 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $14.85 | $0.00 |
DisclosureSEC source: 0001127602-20-027459 · form4.xml · derivative · entry 6 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,522 Underlying: Common Stock · 32,000 shares Expires 2028-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2020. F7 · derivative.exercise_date: 25% of this option will vest and become exercisable on April 9, 2019 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| October 21, 2020 Filed Oct 23, 2020 20:32 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 700 | $71.39 | $49,973.00 |
DisclosureSEC source: 0001127602-20-027459 · form4.xml · nonDerivative · entry 5 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 681 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2020. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.34 to $71.45. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 21, 2020 Filed Oct 23, 2020 20:32 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 15,455 | $70.56 | $1,090,504.80 |
DisclosureSEC source: 0001127602-20-027459 · form4.xml · nonDerivative · entry 4 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,381 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.27 to $71.23. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 21, 2020 Filed Oct 23, 2020 20:32 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 14,148 | $69.84 | $988,096.32 |
DisclosureSEC source: 0001127602-20-027459 · form4.xml · nonDerivative · entry 3 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,836 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.25 to $70.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 21, 2020 Filed Oct 23, 2020 20:32 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 1,697 | $68.70 | $116,583.90 |
DisclosureSEC source: 0001127602-20-027459 · form4.xml · nonDerivative · entry 2 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,984 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.20 to $69.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 21, 2020 Filed Oct 23, 2020 20:32 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 32,000 | $14.85 | $475,200.00 |
DisclosureSEC source: 0001127602-20-027459 · form4.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2020. F2 · balance_after: Includes 681 shares acquired under the Moderna, Inc. 2018 Employee Stock Purchase Plan on May 29, 2020. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 23:24 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 64,000 | $0.00 Strike: $14.85 | $0.00 |
DisclosureSEC source: 0001127602-20-020118 · form4.xml · derivative · entry 3 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,522 Underlying: Common Stock · 64,000 shares Expires 2028-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2020. F3 · derivative.exercise_date: 25% of this option will vest and become exercisable on April 9, 2019 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 23:24 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 64,000 | $63.03 | $4,033,920.00 |
DisclosureSEC source: 0001127602-20-020118 · form4.xml · nonDerivative · entry 2 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 681 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2020. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 23:24 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 64,000 | $14.85 | $950,400.00 |
DisclosureSEC source: 0001127602-20-020118 · form4.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2020. F2 · balance_after: Includes 681 shares acquired under the Moderna, Inc. 2018 Employee Stock Purchase Plan on May 29, 2020. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 64,000 | $0.00 Strike: $14.85 | $0.00 |
DisclosureSEC source: 0001127602-20-017747 · form4.xml · derivative · entry 3 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 463,522 Underlying: Common Stock · 64,000 shares Expires 2028-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: 25% of this option will vest and become exercisable on April 9, 2019 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:14 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 64,000 | $70.00 | $4,480,000.00 |
DisclosureSEC source: 0001127602-20-017747 · form4.xml · nonDerivative · entry 2 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 64,000 | $14.85 | $950,400.00 |
DisclosureSEC source: 0001127602-20-017747 · form4.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 20, 2020 Filed Jun 4, 2020 23:18 UTC Amendment | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 64,000 | $70.00 | $4,480,000.00 |
DisclosureSEC source: 0001127602-20-018904 · form4a.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2020. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:58 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 157,539 | $0.00 Strike: $25.93 | $0.00 |
DisclosureSEC source: 0001127602-20-009092 · form4.xml · derivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,539 Underlying: Common Stock · 157,539 shares Expires 2030-02-28 F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 21:21 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 186,092 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-19-010846 · form4.xml · derivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,092 Underlying: Common Stock · 186,092 shares Expires 2029-03-08 F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:26 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Disposition to issuerOption to Purchase Common Stock · Derivative | 44,251 | $3.34 Strike: $18.41 | $147,798.34 |
DisclosureSEC source: 0001638599-17-000866 · doc4_4892.xml · derivative · entry 16 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,251 shares Expires 2027-02-08 F3 · derivative.exercise_date: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:26 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Disposition to issuerOption to Purchase Common Stock · Derivative | 29,066 | $5.98 Strike: $15.77 | $173,814.68 |
DisclosureSEC source: 0001638599-17-000866 · doc4_4892.xml · derivative · entry 15 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,066 shares Expires 2026-02-04 F3 · derivative.exercise_date: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:26 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Disposition to issuerOption to Purchase Common Stock · Derivative | 22,893 | $4.70 Strike: $17.05 | $107,597.10 |
DisclosureSEC source: 0001638599-17-000866 · doc4_4892.xml · derivative · entry 14 HENDERSON LORI M. · CIK 0001221127 · SVP, Secretary & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,893 shares Expires 2025-03-02 F3 · derivative.exercise_date: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.